Thermo acquires Brahms
Berlin – Global lab supply major Thermo Fisher Scientific Inc. will buy in-vitro diagnostics specialist Brahms AG for about US$470m. The German company employs 400 people and had sales of about a75m last year. Upon completion of the acquisition, expected at the end of September, Brahms will become the European Centre of Excellence of Clinical Diagnostics and part of Thermo Fisher’s Specialty Diagnostics unit. Brahms sells products based on the diagnostic biomarker Procalcitonin (PCT), which is used to detect and monitor anibiotic treatment of sepsis. The company was founded in 1994 and was owned by the management and Swiss investor HBM Bioventures, which pockets net proceeds of a85m. This capital is earmarked to repay a convertible bond due in early 2010.